無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の神経因性疼痛市場

Global Market Study on Neuropathic Pain: Anticonvulsants Drug Class Segment Projected to Witness the Highest Growth Through 2024

発行 Persistence Market Research 商品コード 457223
出版日 ページ情報 英文 145 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.41円で換算しております。
Back to Top
世界の神経因性疼痛市場 Global Market Study on Neuropathic Pain: Anticonvulsants Drug Class Segment Projected to Witness the Highest Growth Through 2024
出版日: 2016年11月29日 ページ情報: 英文 145 Pages
概要

当レポートでは、世界の神経因性疼痛市場について調査し、市場の動向と予測、薬剤クラス別、適応別、流通チャネル別、地域別動向、および市場に参入する主要企業のプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 市場イントロダクション

第3章 市場分析シナリオ

  • 市場規模と予測
  • 市場概要

第4章 市場動向

  • マクロ経済因子
  • 促進因子
  • 阻害因子
  • 機会
  • 予測因子
  • CIPN治療のための薬剤パイプライン分析

第5章 市場分析と予測:薬剤クラス別

  • イントロダクション
  • ベーシスポイントシェア(BPS)分析
  • 前年度比成長予測
  • 市場価値予測
    • 三環系抗鬱剤
    • 抗痙攣剤
    • 局所麻酔剤
    • オピオイド
    • ステロイド
    • その他
  • 市場の魅力度

第6章 市場分析と予測:適応別

  • イントロダクション
  • ベーシスポイントシェア(BPS)分析
  • 前年度比成長予測
  • 市場価値予測
    • 糖尿病性ニューロパシー
    • 化学療法誘発末梢ニューロパシー
    • その他
  • 市場の魅力度

第7章 市場分析と予測:流通チャネル別

  • イントロダクション
  • ベーシスポイントシェア(BPS)分析
  • 前年度比成長予測
  • 市場価値予測
    • 小売薬局
    • ドラッグストア
    • オンライン薬局
    • 中東・アフリカ
  • 市場の魅力度

第8章 市場分析と予測:地域別

  • イントロダクション
  • ベーシスポイントシェア(BPS)分析
  • 前年度比成長予測
  • 市場価値予測
    • 北米
    • ラテンアメリカ
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
  • 市場の魅力度

第9章 北米市場

第10章 ラテンアメリカ市場

第11章 欧州市場

第12章 アジア太平洋地域市場

第13章 中東・アフリカ市場

第14章 競合環境

  • 競合ダッシュボード
  • 企業プロファイル

第15章 予測と略語

第16章 調査方法

目次

This Persistence Market Research report examines the global neuropathic pain market for the period 2016-2024. The primary objective of the report is to offer updates and information related to market opportunities in the global neuropathic pain market and provide insights into developments impacting global businesses and enterprises.

The global neuropathic pain market is segmented on the basis of drug class, indication, distribution channel, and region. This report covers the global neuropathic pain market performance in terms of revenue contribution from various segments and includes a detailed analysis of key trends, drivers, restraints, and opportunities influencing revenue growth of the global neuropathic pain market. Impact analysis of key growth drivers and restraints based on the weighted average model are included in this report to better equip clients with useful decision-making insights. The global neuropathic pain market report begins with an overview of the market and key definitions. The subsequent sections evaluate the present scenario and future growth prospects of the global neuropathic pain market on the basis of drug class, indication, distribution channel, and region and provide a comprehensive market forecast for the next eight years.

The report provides a market outlook for 2016-2024 and sets the forecast within the context of the global neuropathic pain market. The study further analyzes the extent to which drivers are influencing the market across the key assessed regions of North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

In the final section of the report, a competitive market landscape has been included to provide report audiences with a dashboard view of key players operating in the global neuropathic pain market, along with an analysis of company-specific long-term and short-term strategies, key offerings, and recent developments in the global neuropathic pain market. Top market companies featured in the report include Pfizer Inc., Johnson & Johnson Services Inc., Sanofi S.A., Eli Lily and Company, GlaxoSmithKline PLC, Biogen Idec Inc., Bristol-Myers Squibb and Company, Baxter Healthcare Corporation, and Depomed Inc. Persistence Market Research also provides key strategic recommendations for both existing and new players in the global neuropathic pain market to emerge sustainably profitable.

Research methodology

To ascertain the global neuropathic pain market revenue, the report considers regional revenue contribution and contribution of key players operating in the market. The forecast presented in the report assesses the total revenue generated by value across the global neuropathic pain market and in order to provide an accurate forecast, the report begins by sizing the current market, which forms the basis of how the global neuropathic pain market is anticipated to perform in future. Given the ever-fluctuating nature of the global economy, the report not only conducts forecasts in terms of CAGR, but also analyzes the market based on key parameters such as year-on-year (Y-o-Y) growth to understand market predictability and to identify the right opportunities across the global neuropathic pain market. The different market segments and sub-segments have also been analyzed in terms of Basis Point Share (BPS) to understand individual segments' relative contribution to market growth. This detailed level of information is important for identifying various trends impacting the global neuropathic pain market.

Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is overlooked while forecasting the market. Absolute dollar opportunity is critical for evaluating the scope of opportunity that a provider can look to achieve, as well as to identify potential resources in the global neuropathic pain market. The overall absolute dollar opportunity along with the segmental split is mentioned in the report. Further, to understand key market segments in terms of growth and performance in the global neuropathic pain market, Persistence Market Research has developed a market attractiveness index to help providers identify real market opportunities across the global neuropathic pain market.

Table of Contents

1. Executive Summary

2. Market Introduction

  • 2.1. Market Taxonomy
  • 2.2. Market Definition

3. Global Neuropathic Pain Market Analysis Scenario

  • 3.1. Pricing Analysis
    • 3.1.1. Pricing Assumptions
    • 3.1.2. Price Projections Per Region
  • 3.2. Market Size (US$ Mn) and Forecast
    • 3.2.1. Market Size and Y-o-Y Growth
    • 3.2.2. Absolute $ Opportunity

4. Market Dynamics

  • 4.1. Macro-economic Factors
  • 4.2. Drivers
    • 4.2.1. Supply Side
    • 4.2.2. Demand Side
  • 4.3. Restraints
  • 4.4. Opportunity
  • 4.5. Forecast Factors - Relevance and Impact
  • 4.6.Pipeline Analysis of drugs for treatment of CIPN

5. Global Neuropathic Pain Market Analysis and Forecasts, By Drug Class

  • 5.1. Introduction
  • 5.2. Basis Point Share (BPS) Analysis By Drug Class Type
  • 5.3. Y-o-Y Growth Projections By Drug Class Type
  • 5.4. Market Value Forecast By Drug Class, 2016-2024
    • 5.4.1. Tricyclic Antidepressant
    • 5.4.2. Anticonvulsants
    • 5.4.3. Local Anaesthesia
    • 5.4.4. Opioids
    • 5.4.5. Steroids
    • 5.4.6. Others
  • 5.5. Market Attractiveness By Drug Class

6. Global Neuropathic Pain Market Analysis and Forecasts, By Indication

  • 6.1. Introduction
  • 6.2. Basis Point Share (BPS) Analysis By Indication
  • 6.3. Y-o-Y Growth Projections By Indication
  • 6.4. Market Value Forecast By Indication, 2016-2024
    • 6.4.1. Diabetic Neuropathy
    • 6.4.2. Chemotherapy-induced Peripheral Neuropathy
    • 6.4.3. Others
  • 6.5. Market Attractiveness By Indication

7. Global Neuropathic Pain Market Analysis and Forecasts, By Distribution Channel

  • 7.1. Introduction
  • 7.2. Basis Point Share (BPS) Analysis By Distribution Channel
  • 7.3. Y-o-Y Growth Projections By Distribution Channel
  • 7.4. Market Value Forecast By Distribution Channel, 2016-2024
    • 7.4.1. Retail Pharmacies
    • 7.4.2. Drug Stores
    • 7.4.3. Online Pharmacies
  • 7.5. Market Attractiveness By Distribution Channel

8. Global Neuropathic Pain Market Analysis and Forecasts, By Region

  • 8.1. Basis Point Share (BPS) Analysis By Region
  • 8.2. Y-o-Y Growth Projections By Region
  • 8.3. Market Value Forecast By Region
    • 8.3.1. North America
    • 8.3.2. Latin America
    • 8.3.3. Europe
    • 8.3.4. Asia Pacific
    • 8.3.5. Middle East and Africa
  • 8.4. Market Attractiveness By Region

9. North America Neuropathic Pain Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Basis Point Share (BPS) Analysis By Country
    • 9.1.2. Y-o-Y Growth Projections By Country
    • 9.1.3. Key Regulations
  • 9.2. Market Value Forecast By Drug Class, 2016-2024
    • 9.2.1. Tricyclic Antidepressant
    • 9.2.2. Anticonvulsants
    • 9.2.3. Local Anaesthesia
    • 9.2.4. Opioids
    • 9.2.5. Steroids
    • 9.2.6. Others
  • 9.3. Market Value Forecast By Indication, 2016-2024
    • 9.3.1. Diabetic Neuropathy
    • 9.3.2. Chemotherapy-induced Peripheral Neuropathy
    • 9.3.3. Others
  • 9.4. Market Value Forecast By Distribution Channel, 2016-2024
    • 9.4.1. Retail Pharmacies
    • 9.4.2. Drug Stores
    • 9.4.3. Online Pharmacies
  • 9.5. Market Value Forecast By Country, 2016-2024
    • 9.5.1. US
    • 9.5.2. Canada
  • 9.6. Market Attractiveness Analysis
    • 9.6.1. By Drug Class
    • 9.6.2. By Indication
    • 9.6.3. By Distribution Channel
  • 9.7. Drivers and Restraints: Impact Analysis

10. Latin America Neuropathic Pain Market Analysis and Forecast

  • 10.1.Introduction
    • 10.1.1. Basis Point Share (BPS) Analysis By Country
    • 10.1.2. Y-o-Y Growth Projections By Country
    • 10.1.3. Key Regulations
  • 10.2.Market Value Forecast By Drug Class, 2016-2024
    • 10.2.1. Tricyclic Antidepressant
    • 10.2.2. Anticonvulsants
    • 10.2.3. Local Anaesthesia
    • 10.2.4. Opioids
    • 10.2.5. Steroids
    • 10.2.6. Others
  • 10.3.Market Value Forecast By Indication, 2016-2024
    • 10.3.1. Diabetic Neuropathy
    • 10.3.2. Chemotherapy-induced Peripheral Neuropathy
    • 10.3.3. Others
  • 10.4.Market Value Forecast By Distribution Channel, 2016-2024
    • 10.4.1. Retail Pharmacies
    • 10.4.2. Drug Stores
    • 10.4.3. Online Pharmacies
  • 10.5.Market Value Forecast By Country, 2016-2024
    • 10.5.1. Brazil
    • 10.5.2. Mexico
    • 10.5.3. Argentina
    • 10.5.4. Rest of Latin America
  • 10.6.Market Attractiveness Analysis
    • 10.6.1. By Drug Class
    • 10.6.2. By Indication
    • 10.6.3. By Distribution Channel
  • 10.7. Drivers and Restraints: Impact Analysis

11. Europe Neuropathic Pain Market Analysis and Forecast

  • 11.1.Introduction
    • 11.1.1. Basis Point Share (BPS) Analysis By Country
    • 11.1.2. Y-o-Y Growth Projections By Country
    • 11.1.3. Key Regulations
  • 11.2.Market Value Forecast By Drug Class, 2016-2024
    • 11.2.1. Tricyclic Antidepressant
    • 11.2.2. Anticonvulsants
    • 11.2.3. Local Anaesthesia
    • 11.2.4. Opioids
    • 11.2.5. Steroids
    • 11.2.6. Others
  • 11.3.Market Value Forecast By Indication, 2016-2024
    • 11.3.1. Diabetic Neuropathy
    • 11.3.2. Chemotherapy-induced Peripheral Neuropathy
    • 11.3.3. Others
  • 11.4.Market Value Forecast By Distribution Channel, 2016-2024
    • 11.4.1. Retail Pharmacies
    • 11.4.2. Drug Stores
    • 11.4.3. Online Pharmacies
  • 11.5.Market Value Forecast By Country, 2016-2024
    • 11.5.1. UK
    • 11.5.2. France
    • 11.5.3. Germany
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Russia
    • 11.5.7. Rest of Europe
  • 11.6.Market Attractiveness Analysis
    • 11.6.1. By Drug Class
    • 11.6.2. By Indication
    • 11.6.3. By Distribution Channel
  • 11.7. Drivers and Restraints: Impact Analysis

12. Asia Pacific Neuropathic Pain Market Analysis and Forecast

  • 12.1.Introduction
    • 12.1.1. Basis Point Share (BPS) Analysis By Country
    • 12.1.2. Y-o-Y Growth Projections By Country
    • 12.1.3. Key Regulations
  • 12.2.Market Value Forecast By Drug Class, 2016-2024
    • 12.2.1. Tricyclic Antidepressant
    • 12.2.2. Anticonvulsants
    • 12.2.3. Local Anaesthesia
    • 12.2.4. Opioids
    • 12.2.5. Steroids
    • 12.2.6. Others
  • 12.3.Market Value Forecast By Indication, 2016-2024
    • 12.3.1. Diabetic Neuropathy
    • 12.3.2. Chemotherapy-induced Peripheral Neuropathy
    • 12.3.3. Others
  • 12.4.Market Value Forecast By Distribution Channel, 2016-2024
    • 12.4.1. Retail Pharmacies
    • 12.4.2. Drug Stores
    • 12.4.3. Online Pharmacies
  • 12.5.Market Value Forecast By Country, 2016-2024
    • 12.5.1. Japan
    • 12.5.2. China
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
    • 12.5.6.
  • 12.6.Market Attractiveness Analysis
    • 12.6.1. By Drug Class
    • 12.6.2. By Indication
    • 12.6.3. By Distribution Channel
  • 12.7. Drivers and Restraints: Impact Analysis

13. Middle East and Africa Neuropathic Pain Market Analysis and Forecast

  • 13.1.Introduction
    • 13.1.1. Basis Point Share (BPS) Analysis By Country
    • 13.1.2. Y-o-Y Growth Projections By Country
    • 13.1.3. Key Regulations
  • 13.2.Market Value Forecast By Drug Class, 2016-2024
    • 13.2.1. Tricyclic Antidepressant
    • 13.2.2. Anticonvulsants
    • 13.2.3. Local Anaesthesia
    • 13.2.4. Opioids
    • 13.2.5. Steroids
    • 13.2.6. Others
  • 13.3.Market Value Forecast By Indication, 2016-2024
    • 13.3.1. Diabetic Neuropathy
    • 13.3.2. Chemotherapy-induced Peripheral Neuropathy
    • 13.3.3. Others
  • 13.4.Market Value Forecast By Distribution Channel, 2016-2024
    • 13.4.1. Retail Pharmacies
    • 13.4.2. Drug Stores
    • 13.4.3. Online Pharmacies
  • 13.5.Market Value Forecast By Country, 2016-2024
    • 13.5.1. South Africa
    • 13.5.2. UAE
    • 13.5.3. Rest of MEA
  • 13.6.Market Attractiveness Analysis
    • 13.6.1. By Drug Class
    • 13.6.2. By Indication
    • 13.6.3. By Distribution Channel
  • 13.7. Drivers and Restraints: Impact Analysis

14. Competition Landscape

  • 14.1. Competition Dashboard
  • 14.2. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 14.2.1. Pfizer, Inc.
    • 14.2.2. Johnson & Johnson Services, Inc.
    • 14.2.3. Sanofi S.A.
    • 14.2.4. Eli Lily and Company
    • 14.2.5. GlaxoSmithKline PLC
    • 14.2.6. Biogen Idec.
    • 14.2.7. Bristol-Myers Squibb
    • 14.2.8. Baxter Healthcare Corporation
    • 14.2.9 Depomed Inc.

15. Assumptions and Acronyms Used

16. Research Methodology

List of Tables

  • Table 01: Global Neuropathic Pain Market Value (US$ Mn) Analysis and Forecast By Drug Class, 2015-2024
  • Table 02: Global Neuropathic Pain Market Value (US$ Mn) Analysis and Forecast By Indication, 2015-2024
  • Table 03: Global Neuropathic Pain Market Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2015-2024
  • Table 04: Global Neuropathic Pain Market Value (US$ Mn) Analysis and Forecast By Region, 2015-2024
  • Table 05: North America Neuropathic Pain Market Value (US$ Mn) Analysis and Forecast By Country, 2015-2024
  • Table 06: North America Neuropathic Pain Market Value (US$ Mn) Analysis and Forecast By Drug Class, 2015-2024
  • Table 07: North America Neuropathic Pain Market Value (US$ Mn) Analysis and Forecast By Indication, 2015-2024
  • Table 08: North America Neuropathic Pain Market Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2015-2024
  • Table 09: Latin America Neuropathic Pain Market Value (US$ Mn) Analysis and Forecast By Country, 2015-2024
  • Table 10: Latin America Neuropathic Pain Market Value (US$ Mn) Analysis and Forecast By Drug Class, 2015-2024
  • Table 11: Latin America Neuropathic Pain Market Value (US$ Mn) Analysis and Forecast By Indication, 2015-2024
  • Table 12: Latin America Neuropathic Pain Market Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2015-2024
  • Table 13: Europe Neuropathic Pain Market Value (US$ Mn) Analysis and Forecast By Country, 2015-2024
  • Table 14: Europe Neuropathic Pain Market Value (US$ Mn) Analysis and Forecast By Drug Class, 2015-2024
  • Table 15: Europe Neuropathic Pain Market Value (US$ Mn) Analysis and Forecast By Indication, 2015-2024
  • Table 16: Europe Neuropathic Pain Market Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2015-2024
  • Table 17: Asia Pacific Neuropathic Pain Market Value (US$ Mn) Analysis and Forecast By Country, 2015-2024
  • Table 18: Asia Pacific Neuropathic Pain Market Value (US$ Mn) Analysis and Forecast By Drug Class, 2015-2024
  • Table 19: Asia Pacific Neuropathic Pain Market Value (US$ Mn) Analysis and Forecast By Indication, 2015-2024
  • Table 20: Asia Pacific Neuropathic Pain Market Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2015-2024
  • Table 21: Middle East and Africa Neuropathic Pain Market Value (US$ Mn) Analysis and Forecast By Country, 2015-2024
  • Table 22: Middle East and Africa Neuropathic Pain Market Value (US$ Mn) Analysis and Forecast By Drug Class, 2015-2024
  • Table 23: Middle East and Africa Neuropathic Pain Market Value (US$ Mn) Analysis and Forecast By Indication, 2015-2024
  • Table 24: Middle East and Africa Neuropathic Pain Market Value (US$ Mn) Analysis and Forecast By Distribution

List of Figures

  • Figure 01: Global Neuropathic Pain Market Value Share By, Drug Class, 2015 A
  • Figure 02: Global Neuropathic Pain Market Value Share By, Drug Class, 2015 A
  • Figure 03: Global Neuropathic Pain Market Value Share By, Indication, 2015 A
  • Figure 04: Global Neuropathic Pain Market Value Share, By Region, 2015A
  • Figure 05: Tricyclic Antidepressants Pricing Difference (US$) By Region, 2015 A
  • Figure 06: Anticonvulsants Drug Pricing Difference (US$) By Region, 2015 A
  • Figure 07: Local Anaesthesia Pricing Difference (US$) By Region, 2015 A
  • Figure 08: Opioid Pricing Difference Pricing Difference (US$) By Region, 2015 A
  • Figure 09: Global Neuropathic Pain Market Value (US$ Mn) & Y-o-Y Growth (%), 2015-2024
  • Figure 10: Global Neuropathic Pain Market Absolute $ Opportunity, 2016-2024
  • Figure 11: Global Neuropathic Pain Market Share and BPS Analysis (%) By Drug Class, 2016 & 2024
  • Figure 12: Global Neuropathic Pain Y-o-Y growth (%) By Drug Class, 2016-2024
  • Figure 13: Global Neuropathic Pain Market Absolute $ Opportunity By Tricyclic Antidepressants Segment, 2016-2024
  • Figure 14: Global Neuropathic Pain Market Absolute $ Opportunity By Anticonvulsants Segment, 2016-2024
  • Figure 15: Global Neuropathic Pain Market Absolute $ Opportunity By Local Anaesthetics Segment, 2016-2024
  • Figure 16: Global Neuropathic Pain Market Absolute $ Opportunity By Opioids Segment, 2016-2024
  • Figure 17: Global Neuropathic Pain Market Absolute $ Opportunity By Steroids Segment, 2016-2024
  • Figure 18: Global Neuropathic Pain Market Absolute $ Opportunity By Other Drug Segment, 2016-
  • Figure 19: Global Neuropathic Pain Market Attractiveness Analysis By Drug Class, 2016-2024
  • Figure 20: Global Neuropathic Pain Market Share and BPS Analysis (%) By Indication, 2016 & 2024
  • Figure 21: Global Neuropathic Pain Market Y-o-Y Growth Rate (%) By Indication, 2016-2024
  • Figure 22: Global Neuropathic Pain Market Absolute $ Opportunity By CIPN, 2016-2024
  • Figure 23: Global Neuropathic Pain Market Absolute $ Opportunity By Diabetic Neuropathy Segment, 2016-2024
  • Figure 24: Global Neuropathic Pain Market Absolute $ Opportunity By Other Segment, 2016-2024
  • Figure 25: Global Neuropathic Pain Market Attractiveness Analysis By Indication, 2016-2024
  • Figure 26: Neuropathic Pain Market Share Analysis (%) By Distribution Channel, 2016 & 2024
  • Figure 27: Global Neuropathic Pain Y-o-Y growth (%) By Distribution Channel, 2016-2024
  • Figure 28: Global Neuropathic Pain Market Absolute $ Opportunity By Retail Pharmacies Segment, 2016-2024
  • Figure 29: Global Neuropathic Pain Market Absolute $ Opportunity Drug Store Segment, 2016-2024
  • Figure 30: Global Neuropathic Pain Market Absolute $ Opportunity By Online Pharmacies Segment, 2016-2024
  • Figure 31: Global Neuropathic Pain Market Attractiveness Analysis By Distribution Channel, 2016-2024
  • Figure 32: Global Neuropathic Pain Market Value (US$ Mn) and CAGR (%) By Region, 2015, 2020, and 2024
  • Figure 33: Global Neuropathic Pain Market Share Analysis (%) By Region, 2016 & 2024
  • Figure 34: Global Neuropathic Pain Y-o-Y growth (%) By Region, 2016-2024
  • Figure 35: North America Neuropathic Pain Market Absolute $ Opportunity, 2016-2024
  • Figure 36: Latin America Neuropathic Pain Market Absolute $ Opportunity, 2016-2024
  • Figure 37: Europe Neuropathic Pain Market Absolute $ Opportunity, 2016-2024
  • Figure 38: Asia Pacific Neuropathic Pain Market Absolute $ Opportunity, 2016-2024
  • Figure 39: Middle East and Africa Neuropathic Pain Market Absolute $ Opportunity, 2016-2024
  • Figure 40: Global Neuropathic Pain Market Attractiveness Analysis By Region, 2016-2024
  • Figure 41: North America Neuropathic Pain Market Share Analysis (%) By Country, 2016 & 2024
  • Figure 42: North America Neuropathic Pain Y-o-Y growth (%) By Country, 2016-2024
  • Figure 43: North America Neuropathic Pain Market Attractiveness Analysis By Drug Class, 2016-2024
  • Figure 44: North America Neuropathic Pain Market Attractiveness Analysis By Distribution Channel, 2016-2024
  • Figure 45: North America Neuropathic Pain Market Attractiveness Analysis By Indication, 2016-2024
  • Figure 46: Latin America Neuropathic Pain Market Share Analysis (%) By Country, 2016 & 2024
  • Figure 47: Latin America Neuropathic Pain Y-o-Y growth (%) By Country, 2016-2024
  • Figure 48: Latin America Neuropathic Pain Market Attractiveness Analysis By Drug Class, 2016-2024
  • Figure 49: Latin America Neuropathic Pain Market Attractiveness Analysis By Distribution Channel, 2016-2024
  • Figure 50: Latin America Neuropathic Pain Market Attractiveness Analysis By Indication, 2016-2024
  • Figure 51: Europe Neuropathic Pain Market Share Analysis (%) By Country, 2016 & 2024
  • Figure 52: Europe Neuropathic Pain Y-o-Y growth (%) By Country, 2016-2024
  • Figure 53: Europe Neuropathic Pain Market Attractiveness Analysis By Drug Class, 2016-2024
  • Figure 54: Europe Neuropathic Pain Market Attractiveness Analysis By Distribution Channel, 2016-2024
  • Figure 55: Europe Neuropathic Pain Market Attractiveness Analysis By Indication, 2016-2024
  • Figure 56: Asia Pacific Neuropathic Pain Market Share Analysis (%) By Country, 2016 & 2024
  • Figure 57: Asia Pacific Neuropathic Pain Y-o-Y growth (%) By Country, 2016-2024
  • Figure 58: Asia Pacific Neuropathic Pain Market Attractiveness Analysis By Drug Class, 2016-2024
  • Figure 59: Asia Pacific Neuropathic Pain Market Attractiveness Analysis By Distribution Channel, 2016-2024
  • Figure 60: Asia Pacific Neuropathic Pain Market Attractiveness Analysis By Indication, 2016-2024
  • Figure 61: Middle East and Africa Neuropathic Pain Market Share Analysis (%) By Country, 2016 & 2024
  • Figure 62: Middle East and Africa Neuropathic Pain Y-o-Y growth (%) By Country, 2016-2024
  • Figure 63: Middle East and Africa Neuropathic Pain Market Attractiveness Analysis By Drug Class, 2016-2024
  • Figure 64: Middle East and Africa Neuropathic Pain Market Attractiveness Analysis By Distribution Channel, 2016-2024
  • Figure 65: Middle East and Africa Neuropathic Pain Market Attractiveness Analysis By Indication, 2016-2024
Back to Top